LIVN
LivaNova PLC63.08
+0.02+0.03%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
3.44BP/E (TTM)
-Basic EPS (TTM)
-3.98Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
LivaNova appoints seasoned director
LivaNova PLC appointed Donald Zurbay to its Board of Directors and Audit and Compliance Committee, effective September 4, 2025. Zurbay brings two decades of healthcare leadership, including CEO of Patterson Companies until May 2025 and prior CFO roles at Patterson and St. Jude Medical. Compensation follows the company's policy: $70,000 annual retainer, $15,000 committee fee, and $185,000 in prorated restricted stock. This bolsters governance expertise amid medtech demands.
8-K
LivaNova boosts Q2 revenue, guidance
LivaNova reported Q2 2025 revenue of $352.5 million, up 10.7% reported and 10.3% organic, fueled by 14.7% Cardiopulmonary growth from consumables and Essenz sales, while Neuromodulation rose 6.2%. Adjusted EPS climbed to $1.05 from $0.93, with margins expanding to 21.9%. The company raised 2025 guidance to 8.0-9.0% constant-currency revenue growth, $3.70-$3.80 adjusted EPS, and $140-$160 million adjusted free cash flow. VNS Therapy advances in depression and epilepsy bolster neuromodulation momentum, yet SNIA liability weighs on cash.
10-Q
Q2 FY2025 results
LivaNova posted solid Q2 results, with net revenue climbing 10.7% year-over-year to $352.5M, fueled by 14.7% growth in Cardiopulmonary to $199.3M from strong consumables and Essenz system demand, while Neuromodulation edged up 6.2% to $151.7M. Gross margin held steady at 67.8%, but operating income jumped 35.0% to $54.2M thanks to lower 3T litigation provisions and restructuring costs. Yet the six-month picture darkened, as a $362.1M SNIA environmental liability charge—stemming from an Italian Supreme Court ruling on legacy pollution—swung net loss to $300.2M, or $(5.51) diluted EPS on 54.5M shares. Cash swelled to $593.6M after repaying $200M in term debt, yielding $86.9M operating cash flow and $61.3M free cash flow (derived). Debt stands at $430.6M, with $225M revolver available and covenants met. No non-GAAP metrics disclosed in the 10-Q. Regulatory hurdles in depression therapy coverage linger as a key risk.
CVRX
CVRx, Inc.
8.32+0.14
EW
Edwards Lifesciences Corporatio
85.32+1.94
IINN
Inspira Technologies Oxy B.H.N.
1.02-0.03
LUNG
Pulmonx Corporation
2.48-0.07
MDT
Medtronic plc.
97.72-0.85
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NVCR
NovoCure Limited
12.93-0.04
VMD
Viemed Healthcare, Inc.
7.26-0.11
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
VYCO
Vycor Medical, Inc.
0.16+0.00